Thromb Haemost 1983; 49(02): 081-083
DOI: 10.1055/s-0038-1657326
Original Article
Schattauer GmbH Stuttgart

Heparin Counteracts the Antiaggregating Effect of Prostacyclin by Potentiating Platelet Aggregation

Autor*innen

  • Vittorio Bertelé

    The Laboratory for Haemostasis and Thrombosis Research and the Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
  • Maria Carla Roncaglioni

    The Laboratory for Haemostasis and Thrombosis Research and the Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
  • Maria Benedetta Donati

    The Laboratory for Haemostasis and Thrombosis Research and the Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
  • Giovanni de Gaetano

    The Laboratory for Haemostasis and Thrombosis Research and the Laboratory of Cardiovascular Clinical Pharmacology, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
Weitere Informationen

Publikationsverlauf

Received 18. Oktober 1982

Accepted 13. Januar 1983

Publikationsdatum:
18. Juli 2018 (online)

Summary

It has recently been reported that heparin neutralizes the inhibitory effect of prostacyclin (PGI2) on human platelet aggregation. The mechanism of this interaction has not yet been unequivocally established. We present here evidence that heparin (Liquemin Roche) does not react directly with PGI2 but counteracts its inhibitory effect by potentiating platelet aggregation. In the absence of heparin, PGI2 was a less effective inhibitor of platelet aggregation induced by the combination of ADP and serotonin than by ADP alone. Moreover, the inhibitory effect of PGI2 was similarly reduced when increasing the concentrations of ADP (in the absence of heparin). The lack of a specific interaction between heparin and PGI2 is supported by the observation that, in the presence of heparin, other prostaglandins such as PGD2 and PGE1, and a non-prostanoid compound such as adenosine also appeared to lose their inhibitory potency. It is concluded that heparin opposes platelet aggregation inhibitory effect of PGI2 by enhancement of platelet aggregation.